You have 9 free searches left this month | to do more

ofatumumab

Ofatumumab is a drug used to treat Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Arthritis, Rheumatoid, and other conditions. Ofatumumab is being actively studied in 23 studies and prior, has been studied in 43.

Top SponsorsTop SitesTop Investigators
Novartis PharmaceuticalsNovartis Investigative SiteGian Marco Ghiggeri MD, PhD
GlaxoSmithKlineGSK Investigational SiteJennifer R. Brown, MD, PhD
M.D. Anderson Cancer CenterM D Anderson Cancer CenterC. Babis Andreadis
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
H
Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • High Dose Methylprednisolone (HDMP)
  • +2 more
  • Tampa, Florida
    H. Lee Moffitt Cancer Center and Research Institute
2022-03-18
Mar 18, 2022
U
Recruiting
  • Relapsing Remitting Multiple Sclerosis
  • Ofatumumab
  • Los Angeles, California
    University of Southern California
2022-02-03
Feb 3, 2022
N
Terminated
  • Relapsing Forms of Multiple Sclerosis
  • Lutherville, Maryland
  • +1 more
2022-02-28
Feb 28, 2022
M
Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Ofatumumab
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
2022-02-23
Feb 23, 2022
N
Recruiting
  • Relapse Remitting Multiple Sclerosis
  • Ofatumumab
  • Knoxville, Tennessee
    Novartis Investigative Site
2022-02-28
Feb 28, 2022
N
Recruiting
  • Relapsing-Remitting Multiple Sclerosis
  • Ofatumumab
  • Disease modifying treatment (DMT)
  • Knoxville, Tennessee
    Novartis Investigative Site
2022-04-05
Apr 5, 2022
H
Active, not recruiting
  • Chronic Graft Versus Host Disease
  • Ofatumumab
  • Phoenix, Arizona
  • +3 more
2021-11-15
Nov 15, 2021
M
Active, not recruiting
  • Leukemia
  • Lymphoma
  • Ofatumumab
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
2021-07-30
Jul 30, 2021
B
Recruiting
  • Relapsing Multiple Sclerosis
  • Boston, Massachusetts
    Partners MS Center, 60 Fenwood Road
2021-07-20
Jul 20, 2021
N
Completed
  • Relapsing Multiple Sclerosis
  • Ofatumumab
  • Matching placebo of ofatumumab
  • Toon-city, Ehime, Japan
  • +13 more
2021-12-02
Dec 2, 2021
N
Recruiting
  • Relapsing Multiple Sclerosis (RMS)
  • Ofatumumab
  • +2 more
  • Phoenix, Arizona
  • +3 more
2022-01-19
Jan 19, 2022
N
Recruiting
  • Relapsing Multiple Sclerosis
  • Quadrivalent influenza vaccine
  • Ofatumumab
  • Phoenix, Arizona
  • +3 more
2021-08-30
Aug 30, 2021
D
Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Boston, Massachusetts
  • +2 more
2021-08-09
Aug 9, 2021
H
Completed
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • High Dose Methylprednisolone (HDMP)
  • +2 more
  • Tampa, Florida
    H. Lee Moffitt Cancer Center and Research Institute
2021-04-02
Apr 2, 2021
N
Active, not recruiting
  • Small Lymphocytic Lymphoma
  • CLL (Chronic Lymphocytic Leukemia)
  • Fludarabine Phosphate
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
2022-04-06
Apr 6, 2022
P
Completed
  • Diffuse Large B Cell Lymphoma
  • Ofatumumab
  • +7 more
  • Wrocław, Dolnośląskie, Poland
  • +7 more
2021-12-23
Dec 23, 2021
N
Recruiting
  • Relapsing Multiple Sclerosis
  • Ofatumumab
  • Birmingham, Alabama
  • +16 more
2022-03-22
Mar 22, 2022
N
G
Completed
  • Chronic Lymphocytic Leukemia
  • Cologne, Germany
    German CLL Study Group
2020-06-09
Jun 9, 2020
I
Terminated
  • Nephrotic Syndrome
  • Ofatumumab
  • Placebo
  • Genoa, Italy/GE, Italy
    IRCCS Istituto Giannina Gaslini
2020-07-28
Jul 28, 2020
I
Completed
  • Nephrotic Syndrome
  • Genoa, Italy/GE, Italy
    IRCCS Istituto Giannina Gaslini
2020-07-28
Jul 28, 2020
M
Completed
  • Lymphoma
  • Ofatumumab
  • +5 more
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
2020-06-19
Jun 19, 2020
N
Recruiting
  • Multiple Sclerosis
  • Ofatumumab
  • First line DMT
  • Bayonne, Bayonne Cedex, France
  • +33 more
2022-03-25
Mar 25, 2022